SCHEMBL16913997

SCHEMBL16913997

COc1ccc(COc2cnc(Cl)nc2NC2(CO)CCCC2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 2/20 0.36
▸ RAB9A P51151 2/20 0.36
▸ POLB P06746 3/20 0.35
▸ KDM4E B2RXH2 2/20 0.35
▸ LMNA P02545 2/20 0.35
▸ MAPT P10636 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ SPHK2 Q9NRA0 1/20 0.35
▸ MAOB P27338 1/20 0.34
▸ HRH3 Q9Y5N1 1/20 0.34
▸ CSF1R P07333 4/20 0.34
▸ CCNE2 O96020 1/20 0.34
▸ CCNE1 P24864 1/20 0.34
▸ CDK2 P24941 1/20 0.34
▸ LATS1 O95835 1/20 0.34
▸ LATS2 Q9NRM7 1/20 0.34
▸ NTRK1 P04629 1/20 0.34
▸ NTRK3 Q16288 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16914145 0.96 NPC1 (0.37) NPC1RAB9APOLBKDM4ELMNA
SCHEMBL16914209 0.91 SMN1; SMN2 (0.36) NPC1RAB9APOLBKDM4ELMNA
SCHEMBL16914256 0.88 NPC1 (0.34) NPC1RAB9APOLBKDM4ELMNA
SCHEMBL16685622 0.73 NPC1 (0.48) NPC1RAB9APOLBLMNAMAPT
SCHEMBL16914116 0.73 HRH3 (0.37) NPC1RAB9APOLBKDM4EMEN1
SCHEMBL16914119 0.73 HRH3 (0.37) NPC1RAB9APOLBKDM4EMEN1
SCHEMBL16914118 0.73 HRH3 (0.37) NPC1RAB9APOLBKDM4EMEN1
SCHEMBL16914085 0.72 LATS1 (0.41) KMT2ACCNE2CCNE1CDK2LATS1
SCHEMBL16914178 0.71 KDM4E (0.35) NPC1RAB9APOLBKDM4ELMNA
SCHEMBL16685593 0.71 ABCB1 (0.42) NPC1RAB9AKDM4ELMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9771378-B2 Fused morpholinopyrimidines and methods of use thereof DENALI THERAPEUTICS, INC. (US) 2017-09-26 — — US disclosed
US-9771378-B2 Fused morpholinopyrimidines and methods of use thereof DENALI THERAPEUTICS, INC. (US) 2017-09-26 — — US disclosed
US-20170044182-A1 FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF FORUM PHARMACEUTICALS INC. 2017-02-16 — — US disclosed
US-20170044182-A1 FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF FORUM PHARMACEUTICALS INC. 2017-02-16 — — US disclosed
WO-2015138689-A1 FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF FORUM PHARMACEUTICALS INC. (US) 2015-09-17 — — WO disclosed
WO-2015138689-A1 FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF FORUM PHARMACEUTICALS INC. (US) 2015-09-17 — — WO disclosed
WO-2015109109-A1 FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF FORUM PHARMACEUTICALS INC. (US) 2015-07-23 — — WO disclosed
WO-2015109109-A1 FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF FORUM PHARMACEUTICALS INC. (US) 2015-07-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170044182-A1 FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF SMN1; SMN2, FUS, SYNCRIP NPC1 622/4885RAB9A 2507/4885POLB 314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback